	US 11,897,965 B2
	Anti-Jagged1 antigen binding proteins
Brian D. Bennett, Thousand Oaks, CA (US); Chadwick T. King, North Vancouver (CA); and Jonathan Phillips, Simi Valley, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Feb. 16, 2022, as Appl. No. 17/672,889.
Application 17/320,128 is a division of application No. 15/993,448, filed on May 30, 2018, granted, now 11,028,180, issued on Jun. 8, 2021.
Application 17/672,889 is a continuation of application No. 17/320,128, filed on May 13, 2021.
Claims priority of provisional application 62/512,805, filed on May 31, 2017.
Prior Publication US 2022/0169744 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61P 37/00 (2006.01); C07K 14/52 (2006.01); C07K 14/475 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61P 37/00 (2018.01); C07K 16/22 (2013.01); A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/20 (2013.01)]

18 Claims

1. An isolated antigen binding protein that specifically binds to a human Jaggedl polypeptide; wherein the antigen binding protein is an antibody or a fragment thereof; wherein the antibody or a fragment thereof comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3; and wherein CDRL1 comprises SEQ ID NO:

98, CDRL2 comprises SEQ ID NO: 99, CDRL3 comprises SEQ ID NO: 100, CDRH1 comprises SEQ ID NO: 230, CDRH2 comprises SEQ ID NO: 231, and CDRH3 comprises SEQ ID NO: 232.